Human Granzyme B Quantikine HS ELISA Kit

Catalog #: HSGZB0
1 Citation 1 Review Datasheet

Catalog #	Availability	Size / Price	Qty
HSGZB0

Control Products Available

QC274: Quantikine Immunoassay Control 1032 for Human HS Granzyme B

2 Images

All Granzyme B ELISAs

Product Details

Citations (1)

FAQs

Supplemental Products

Reviews (1)

Summary Precision Recovery Data Examples Product Datasheets Preparation and Storage Background Related Research Areas

Human Granzyme B Quantikine HS ELISA Kit Summary

Assay Length

4.0 Hours

Sample Type & Volume Required Per Well

Serum (50 uL), Plasma (50 uL), Heparin Plasma (13 uL), Saliva (25 uL)

Sensitivity

0.412 pg/mL

Assay Range

1.1 - 70 pg/mL (Serum, Plasma, Heparin Plasma, Saliva)

Specificity

Natural and recombinant human Granzyme B.

Cross-reactivity

< 0.5% cross-reactivity observed with available related molecules.< 50% cross-species reactivity observed with species tested.

Interference

No significant interference observed with available related molecules.

Product Summary

The Quantikine^® HS Human Granzyme B Immunoassay is a 4.0 hour solid-phase ELISA designed to measure human Granzyme B in serum, plasma and saliva. It contains NS0-expressed recombinant human Granzyme B and antibodies raised against the recombinant protein. Results obtained using natural human Granzyme B showed linear curves that were parallel to

the standard curves obtained using the Quantikine^® kit standards. These results indicate that this kit can be used to determine relative mass values for natural human Granzyme B.

Precision

Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision

Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians

Serum, Plasma, Heparin Plasma, Saliva

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	20	20	20	20	20	20
Mean (pg/mL)	10.5	16.5	42.8	10.8	17	42.9
Standard Deviation	0.117	0.267	0.566	0.627	0.83	2.02
CV%	1.1	1.6	1.3	5.8	4.9	4.7

Recovery

The recovery of human Granzyme B spiked to levels throughout the range of the assay was evaluated.

Sample Type	Average % Recovery	Range %
EDTA Plasma (n=4)	106	101-111
Heparin Plasma (n=4)	103	97-109
Saliva (n=4)	100	95-105
Serum (n=4)	108	101-115

Scientific Data

N/A

View Larger

Human Granzybe B HS ELISA

Product Datasheets

Product Datasheet

Preparation and Storage

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Storage

Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Background: Granzyme B

Granzyme B is a member of the granzyme family of serine proteases found specifically in granules of cytotoxic T lymphocytes (CTL) and natural killer (NK) cells (1, 2). Granzyme B plays an essential role in granule-mediated apoptosis utilizing the substrates in this pathway, such as Caspase 3, Caspase 8 and Bid (3, 4). Recent research indicates expanded Granzyme B functionality to include extracellular roles along with its classical pro-apoptotic function. It has been found that Granzyme B is an important mediator of skin injury, repair and inflammation (4) through extracellular substrates including Laminin, VE-Cadherin, Fibronectin and the proteoglycans Aggrecan (3) and Decorin (4).

As one of the five Granzymes (A, B, H, K and M) identified in the human genome, Granzyme B (32kDa) (5) is the most widely researched in terms of its biological function and its utility in health and disease (4). It is synthesized as a precursor (247 residues) with a signal peptide (residues 1-18), a pro-peptide (residues 19-20), and a mature chain (residues 21-247) (6-8). Once inside granules, Granzyme B is fully processed into the mature chain and becomes an active protease when the pro-peptide, Gly-Glu is removed from the N-terminus by cleavage with Cathepsin C (9). The protease activity of Granzyme B is tightly controlled by Serpin B9/ Protease Inhibitor 9 (9). The amino acid sequence of human Granzyme B is 71%, 69%, and 68% identical to its canine, rat, and mouse counterparts, respectively.

Granzymes have been shown to modulate inflammation, and Granzyme B plasma levels have been found higher with atopic dermatitis and psoriasis when compared to healthy controls. This is in contrast to Granzyme A plasma levels which remain unchanged (10). Serum from patients with Crohn's disease have significantly higher Granzyme B levels than controls (11).

Entrez Gene IDs:

3002 (Human); 14939 (Mouse)

Alternate Names:

C11; CCPI; CGL1; CGL-1; CSPB; CSP-B; CTLA1; CTLA-1; CTSGL1; Fragmentin-2; Granzyme B; Granzyme-2; GranzymeB; GRB; GrzB; GZMB; HLP; SECT

Related Research Areas

Citation for Human Granzyme B Quantikine HS ELISA Kit

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

1 Citation: Showing 1 - 1